HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 04, April 2021 – The Evolution of Medicine – Exploring the Contributions of Sony’s Technology       » Potential Target and Neural Circuitry for Psychiatric Conditions       » Study Provides Insight to Cause of Coral Necrotic Death       » Combination of X-Rays and AI for Quicker Diagnosis of COVID-19       » Clinical Study Achieves Goals in Diagnosing Rare Childhood Disorders       » Portable Device to Detect Plant Stress      
NEWS CRUNCH
Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Group
Proteona Honoured with

SINGAPORE | 7th July 2020

Singapore-based biomedical company, Proteona, is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).

It has recently been selected by the Spinoff Prize as one of the top 44 science-based spin-off companies from around the world. The Spinoff Prize is established by Nature Research in partnership with the Merck Group. The award highlights spin-offs who take top-quality scientific research to the market and make a positive impact.

Proteona is recognized for addressing the clinical need in multiple myeloma, a blood cancer that is difficult to treat. Differences in drug response between patients and tumour clones within the same patient poses a great challenge in choosing the right treatment. Proteona leverages on single cell proteogenomics and artificial intelligence-assisted algorithms to measure tumour cell diversity in patient biopsy, which can help clinicians choose the best treatment for individual patient.

"It is a great honour to be recognized by the Spinoff Prize award, issued by Nature research, who represents the top scientific standard, and by Merck, an industry leader well known for its accelerator programs and technology innovation." Said Dr Andreas Schmidt, CEO of Proteona.

"It adds credibility to the science and business we are doing at Proteona, and provides momentum for us to achieve the next milestones. This comes just at the right moment for our upcoming fundraising campaign, which will be launched in a few weeks' time."

Proteona is one of the three Asia-based companies who made it to the prestigious list.

The Spinoff Prize application was open to all spinoff companies worldwide from fields of pharmaceuticals, agriculture, chemicals and digital technology. The companies were selected by a judging panel consisting of experts from Nature Research, Merck, and M Ventures. All companies were evaluated in five criteria: the science, the opportunity, the plan, the team, and the impact.

Proteona is committed to improving the clinical outcome of multiple myeloma. Proteona has recently been selected by Amgen as part of the Start-ups Meets Pharma program to improve multiple myeloma treatment selection.

NEWS CRUNCH  
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
news CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
news Highlights from the E&L China 2020 Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy